About This Scorecard
A data-forward scorecard of the metabolic-peptide literature — tesamorelin and retatrutide, scored at the strength the trials support.
What Vyra Peptides is
Vyra Peptides is a scorecard for two peptides at the front of metabolic science: tesamorelin and retatrutide, read through the lens of visceral-fat research. It exists to make a dense, fast-moving literature legible — to say, in plain language and with precise citations, what each compound was studied in, what numbers were measured, and how far those numbers actually extend. Effect sizes, confidence intervals, study populations, and regulatory status are the working vocabulary; mechanisms get explained in accessible terms, but the data are never softened or stretched past what the studies showed.
Tesamorelin is the lead: the only GHRH analogue with FDA approval, and the most precisely characterised visceral-fat data in metabolic-peptide research. Retatrutide is its investigational counterpart — a triple receptor agonist whose Phase 2 signal is the largest in the incretin class, with Phase 3 still running. Scored side by side, they show how far metabolic pharmacology moved in the decade between their trial generations.
How it is compiled
Three principles govern what appears on this site.
First, every research claim is anchored to the peer-reviewed literature. All citations are numbered and collected on the references page, linking to PubMed, PubMed Central, or the journal of record. Effect sizes are quoted with sample sizes, durations, and confidence intervals where the study reported them — not paraphrased into impressionistic phrases.
Second, the evidence is reported at its actual strength. Where trials were conducted in a specific population (HIV-positive adults, patients with type 2 diabetes), that population boundary is stated plainly — not glossed over as "people." Where retatrutide's Phase 3 outcomes are pending, this is noted rather than bridged with Phase 2 extrapolation. Regulatory approval status and WADA classification are treated as scientific facts, not legal disclaimers.
Third, limitations are part of the record. Visceral fat reaccumulation on tesamorelin discontinuation, the gray-market purity problem for research-grade retatrutide, the heart-rate signal in Phase 2 — these belong in the research summary, not in a footnote.
What it is not
A scorecard is not a store, a clinic, or a weight-loss program. Vyra Peptides sells, supplies, sources, and brokers nothing, and holds no affiliate or referral tie to any supplier or vendor. It keeps no clinicians, diagnoses nothing, prescribes nothing, and recommends no regimen.
No human dose appears anywhere on the site. The phrase 'studied at [dose] in [population]' shows up often — that reports what a trial did, not what a reader should do. The compounds here are either narrow-indication prescription drugs (tesamorelin, outside its HIV-lipodystrophy indication) or investigational agents with no approved indication (retatrutide); neither is an over-the-counter or self-directed supplement. Anyone interested in the metabolic conditions the research describes should consult a licensed clinician in their own jurisdiction.